Zacks: Brokerages Expect Kamada Ltd. (NASDAQ:KMDA) Will Announce Earnings of $0.15 Per Share

Wall Street analysts expect Kamada Ltd. (NASDAQ:KMDA) to announce earnings per share (EPS) of $0.15 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Kamada’s earnings. The highest EPS estimate is $0.17 and the lowest is $0.12. Kamada reported earnings per share of $0.14 during the same quarter last year, which indicates a positive year-over-year growth rate of 7.1%. The business is scheduled to issue its next quarterly earnings results on Tuesday, August 6th.

On average, analysts expect that Kamada will report full-year earnings of $0.51 per share for the current fiscal year, with EPS estimates ranging from $0.43 to $0.61. For the next fiscal year, analysts anticipate that the company will post earnings of $0.52 per share, with EPS estimates ranging from $0.32 to $0.72. Zacks’ earnings per share averages are an average based on a survey of research analysts that that provide coverage for Kamada.

Kamada (NASDAQ:KMDA) last released its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported $0.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.04 by $0.08. The firm had revenue of $26.80 million during the quarter, compared to analyst estimates of $22.87 million. Kamada had a return on equity of 24.75% and a net margin of 20.97%.

A number of equities analysts have recently weighed in on KMDA shares. Chardan Capital set a $8.00 price objective on OncoCyte and gave the stock a “buy” rating in a research note on Friday, May 17th. Zacks Investment Research raised Golub Capital BDC from a “hold” rating to a “buy” rating and set a $20.00 price objective for the company in a research note on Tuesday. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $8.17.

Institutional investors have recently made changes to their positions in the stock. Nkcfo LLC bought a new position in Kamada during the first quarter valued at approximately $26,000. Norges Bank bought a new position in Kamada during the fourth quarter valued at approximately $219,000. Marshall Wace LLP bought a new position in Kamada during the first quarter valued at approximately $276,000. Meitav Dash Investments Ltd. boosted its stake in Kamada by 3.1% during the first quarter. Meitav Dash Investments Ltd. now owns 909,912 shares of the biotechnology company’s stock valued at $5,201,000 after buying an additional 27,405 shares during the last quarter. Finally, Acadian Asset Management LLC boosted its stake in Kamada by 41.8% during the first quarter. Acadian Asset Management LLC now owns 945,878 shares of the biotechnology company’s stock valued at $5,422,000 after buying an additional 278,674 shares during the last quarter. 12.98% of the stock is owned by institutional investors.

Shares of NASDAQ KMDA traded down $0.03 during mid-day trading on Monday, reaching $5.94. The company’s stock had a trading volume of 25,004 shares, compared to its average volume of 30,604. The company has a market cap of $240.37 million, a price-to-earnings ratio of 9.33 and a beta of 1.17. The company has a quick ratio of 3.82, a current ratio of 5.29 and a debt-to-equity ratio of 0.04. The firm’s fifty day simple moving average is $5.61. Kamada has a 52 week low of $4.63 and a 52 week high of $6.70.

Kamada Company Profile

Kamada Ltd. develops, produces, and markets plasma-derived protein therapeutics for orphan indications. It operates through two segments, Proprietary Products and Distribution. The company offers respiratory products, including Glassia for use in augmentation and maintenance therapy in adults with emphysema due to congenital Alpha-1 Antitrypsin (AAT) deficiency.

See Also: Stock Symbols, CUSIP and Other Stock Identifiers

Get a free copy of the Zacks research report on Kamada (KMDA)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Kamada (NASDAQ:KMDA)

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with's FREE daily email newsletter.